Transgene Biotek Ltd
₹ 3.01
3.44%
31 Jul
- close price
About
Incorporated in 1990, Transgene Biotek Ltd
is in the business of Research & Development[1]
Key Points
- Market Cap ₹ 22.8 Cr.
- Current Price ₹ 3.01
- High / Low ₹ 5.17 / 1.83
- Stock P/E
- Book Value ₹ -1.21
- Dividend Yield 0.00 %
- ROCE -7.91 %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 23.6%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Upcoming result date: 7 August 2026
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.30 | 0.18 | 0.28 | 0.12 | 0.07 | 0.00 | 0.17 | 0.09 | 0.06 | 0.23 | 0.26 | 0.21 | |
| 1.81 | 1.32 | 2.84 | 5.12 | 0.75 | 0.87 | 0.70 | 0.55 | 0.68 | 0.83 | 1.38 | 0.75 | |
| Operating Profit | -1.51 | -1.14 | -2.56 | -5.00 | -0.68 | -0.87 | -0.53 | -0.46 | -0.62 | -0.60 | -1.12 | -0.54 |
| OPM % | -503.33% | -633.33% | -914.29% | -4,166.67% | -971.43% | -311.76% | -511.11% | -1,033.33% | -260.87% | -430.77% | -257.14% | |
| 0.01 | 0.17 | 0.66 | 10.27 | 2.04 | 0.18 | 0.27 | 0.21 | 0.18 | 0.18 | 0.78 | 0.15 | |
| Interest | 0.36 | 0.07 | 0.43 | 1.03 | 0.26 | 0.38 | 0.27 | 0.23 | 0.62 | 0.14 | 0.24 | 1.06 |
| Depreciation | 17.18 | 20.50 | 17.53 | 9.89 | 9.89 | 9.90 | 9.91 | 9.92 | 4.95 | 0.09 | 0.09 | 0.20 |
| Profit before tax | -19.04 | -21.54 | -19.86 | -5.65 | -8.79 | -10.97 | -10.44 | -10.40 | -6.01 | -0.65 | -0.67 | -1.65 |
| Tax % | 0.00% | 0.00% | 0.00% | 13.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| -19.04 | -21.54 | -19.86 | -6.44 | -8.79 | -10.96 | -10.43 | -10.40 | -6.01 | -0.66 | -0.68 | -1.65 | |
| EPS in Rs | -2.51 | -2.84 | -2.62 | -0.85 | -1.16 | -1.45 | -1.38 | -1.37 | -0.79 | -0.09 | -0.09 | -0.22 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 4% |
| 3 Years: | 52% |
| TTM: | -19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 13% |
| 3 Years: | 20% |
| TTM: | -143% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -6% |
| 3 Years: | -7% |
| 1 Year: | -34% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 |
| Reserves | 102.38 | 78.89 | -34.48 | -40.92 | -49.71 | -60.67 | -71.11 | -75.97 | -81.98 | -82.64 | -83.32 | -84.97 |
| 14.34 | 15.28 | 16.01 | 9.84 | 9.14 | 10.33 | 11.33 | 12.02 | 13.12 | 14.00 | 14.52 | 17.14 | |
| 137.84 | 123.15 | 30.88 | 31.97 | 31.45 | 31.43 | 31.01 | 25.40 | 25.57 | 25.31 | 27.23 | 25.82 | |
| Total Liabilities | 330.33 | 293.09 | 88.18 | 76.66 | 66.65 | 56.86 | 47.00 | 37.22 | 32.48 | 32.44 | 34.20 | 33.76 |
| 163.40 | 140.95 | 61.16 | 50.97 | 41.10 | 31.20 | 21.32 | 11.40 | 6.45 | 6.36 | 7.96 | 9.63 | |
| CWIP | 0.29 | 0.29 | 2.04 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 0.00 |
| Investments | 92.20 | 92.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.11 | 0.11 | 0.10 | 0.10 | 0.09 |
| 74.44 | 59.65 | 24.98 | 23.82 | 23.68 | 23.79 | 23.80 | 23.84 | 24.05 | 24.11 | 24.27 | 24.04 | |
| Total Assets | 330.33 | 293.09 | 88.18 | 76.66 | 66.65 | 56.86 | 47.00 | 37.22 | 32.48 | 32.44 | 34.20 | 33.76 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.95 | 0.02 | 0.02 | -0.63 | -1.74 | 0.14 | 0.01 | 0.10 | 0.00 | 0.00 | 1.20 | -0.01 | |
| -0.02 | -0.02 | 0.00 | 3.05 | 1.74 | 0.00 | -0.04 | -0.10 | -0.01 | 0.00 | -1.70 | 0.15 | |
| 0.94 | 0.00 | 0.00 | -2.37 | 0.00 | -0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.78 | -0.36 | |
| Net Cash Flow | -0.02 | 0.00 | 0.02 | 0.05 | 0.00 | -0.06 | -0.02 | 0.00 | -0.01 | 0.00 | 0.28 | -0.22 |
| Free Cash Flow | -0.95 | 0.02 | 0.02 | 2.74 | -0.01 | 0.14 | -0.02 | 0.10 | 0.00 | 0.00 | -0.50 | 0.14 |
| CFO/OP | 63% | -2% | -1% | 13% | 256% | -16% | -2% | -22% | 0% | 0% | -107% | 2% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 19,941.17 | 3,305.28 | 13.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventory Days | 365.00 | 365.00 | 1,460.00 | 121.67 | 156.43 | |||||||
| Days Payable | 5,018.75 | 3,528.33 | 13,870.00 | 1,460.00 | 1,199.29 | |||||||
| Cash Conversion Cycle | 19,941.17 | 3,305.28 | 13.04 | -4,653.75 | -3,163.33 | -1,338.33 | 0.00 | -1,042.86 | 0.00 | 0.00 | 0.00 | |
| Working Capital Days | -8,285.50 | -15,796.39 | -14,208.93 | -39,663.33 | -61,997.86 | -28,856.47 | -34,188.33 | -56,696.67 | -15,790.22 | -16,354.81 | -21,170.00 | |
| ROCE % | -9.27% | -11.85% | -17.10% | -14.75% | -25.79% | -34.93% | -49.11% | -73.14% | -57.55% | -7.26% | -6.10% | -7.91% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Employee Benefit Expense Rs. Lakhs |
|
|||||||||
| Intangible Assets Under Development Rs. Lakhs |
||||||||||
| Property, Plant and Equipment (Net Block) Rs. Lakhs |
||||||||||
| Technology Intangible Assets (Net Book Value) Rs. Lakhs |
||||||||||
| Patent Application Filing Fees Rs. Lakhs |
||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Intimation Of The Board Meeting.
23 Jul - Board meeting on August 7, 2026 to approve Q1 FY27 results and seek AGM extension.
-
Compliance-57 (4) : Prior intimation to the beginning of the quarter
22 Jul - Company states Regulation 57 is not applicable for quarter ended 30.06.2026.
-
Statement Of Deviation & Variation
22 Jul - Regulation 32 not applicable for quarter ended 30 June 2026; no public, rights, or preferential issue.
-
Compliance-57 (5) : intimation after the end of quarter
22 Jul - Transgene Biotek says Reg. 57(5) is not applicable for quarter ended 30 June 2026.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 13 Jul
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
TBL started as a Biotechnology company engaged in the manufacturing and selling diagnostic kits. The company expanded to biotech research, including the research and development of vaccines, oncology, New drug delivery technologies etc. Currently, the company has a product and technology portfolio covering Oncology, Oral Drug Delivery and Bio-generics.